Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fifteen analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has